Life expectancy with stage 4 cancer varies enormously depending on where the cancer started. Five-year survival rates range from as low as 3% for pancreatic cancer to over 40% for prostate cancer. No single number applies to “stage 4 cancer” as a whole, because the biology, available treatments, and response to therapy differ dramatically by cancer type.
Stage 4 means the cancer has spread (metastasized) from its original site to distant organs like the bones, liver, lungs, or brain. Survival statistics are reported as “5-year relative survival rates,” which measure the percentage of people with that diagnosis who are alive five years later compared to the general population. These are population averages. They don’t predict what will happen to any individual person.
Survival Rates by Cancer Type
The numbers below reflect the most recent data from the National Cancer Institute’s SEER program, which tracks cancer outcomes across the United States.
Lung cancer has one of the lower survival rates at stage 4, but it has improved significantly in recent years. The current 5-year survival rate for distant non-small cell lung cancer is 12%, based on patients diagnosed between 2015 and 2021. Older data from 2008 to 2014 showed rates closer to 4-6%, so the jump reflects real progress in treatment.
Breast cancer that has metastasized carries a 5-year survival rate of about 31%, according to NCI data from 2013 to 2019. Survival varies by subtype. Cancers that are hormone receptor-positive tend to respond better to treatment, while those that have spread to the brain carry a worse prognosis than cancer that has spread only to bone or lymph nodes.
Prostate cancer at the distant stage has a 5-year survival rate of about 40%, making it one of the more survivable stage 4 diagnoses. Prostate cancer often grows slowly and responds well to hormone-based treatments, which can control the disease for years.
Colorectal cancer that has spread to distant sites has a 5-year survival rate of about 17%, based on SEER data from 2016 to 2022.
Pancreatic cancer remains the most difficult. The 5-year survival rate for distant-stage pancreatic cancer is 3.4%. This cancer is often diagnosed late and tends to resist many standard treatments.
What Affects an Individual’s Prognosis
Population statistics describe averages, but several factors shift the outlook for any one person, sometimes substantially.
The number of places the cancer has spread matters a great deal. Research on metastatic breast cancer found that people with cancer in two distant sites had roughly 1.4 times the risk of death compared to those with a single site. With five or more metastatic sites, the risk jumped to four times higher. Having cancer in just one location, especially bone or lymph nodes rather than the brain, is consistently associated with longer survival.
Where the cancer has spread is just as important as how many places it has reached. Brain metastases carry a worse prognosis than spread to bone, liver, or lung across most cancer types. In that same breast cancer analysis, people with cancer only outside the brain survived significantly longer than those with brain involvement.
Overall health plays a major role. People with fewer other medical conditions at the time of their cancer diagnosis live longer on average. As the burden of other health problems increases, survival decreases in a clear, stepwise pattern. Age, nutritional status, and physical fitness all feed into how well someone tolerates treatment and how long they can continue it.
The biology of the tumor itself, including specific molecular markers that oncologists test for, determines which treatments are available. Some tumor profiles open the door to targeted therapies or immunotherapies that can dramatically extend life. Others limit options to standard chemotherapy.
How Treatment Has Changed the Numbers
The survival statistics published today are based on patients diagnosed years ago and don’t fully capture the impact of newer therapies. This is important context when you’re reading stage 4 survival data: the numbers are always somewhat outdated by design, because you need years of follow-up to calculate them.
Melanoma is the most striking example of how quickly the landscape can shift. A little over a decade ago, stage 4 melanoma had a median survival of just 6 to 8 months. Today, combination immunotherapy has pushed median survival beyond 3 years. In the landmark CheckMate 067 trial, 49% of patients receiving combination checkpoint immunotherapy were alive at 6.5 years, and some appear to be cured. That kind of transformation was unimaginable in melanoma just 15 years ago.
Lung cancer survival has similarly benefited from immunotherapy and targeted treatments. The jump from a 4-5% five-year survival rate to 12% over the span of a few years reflects these newer options becoming standard care. For patients whose tumors have specific genetic mutations or high levels of certain proteins, the outlook can be considerably better than the average suggests.
Not every cancer type has seen the same progress. Pancreatic cancer survival has barely budged, and some gastrointestinal cancers remain stubbornly resistant to newer approaches. The pace of improvement is uneven.
What These Numbers Don’t Tell You
Survival statistics describe what happened to large groups of people in the past. They cannot account for treatments approved in the last few years, clinical trials you might be eligible for, or the specific biology of your tumor. Two people with the same stage 4 diagnosis can have very different outcomes based on their tumor’s molecular profile, where it has spread, and how it responds to initial treatment.
It’s also worth understanding that “5-year survival rate” doesn’t mean you only live five years. It’s a snapshot at the five-year mark. Many people in the surviving percentage continue living well beyond that point. For cancers like prostate or certain breast cancer subtypes, stage 4 can behave more like a chronic illness managed over many years than a rapidly terminal diagnosis.
Quality of life during treatment is another dimension these numbers don’t capture. Modern supportive care, including pain management, anti-nausea therapies, and rehabilitation, has improved substantially. Living longer with stage 4 cancer increasingly means living with a better day-to-day experience than was possible a generation ago, even when cure isn’t realistic.